CN100569771C - 作为5-ht4受体激动剂的喹啉酮-甲酰胺化合物 - Google Patents

作为5-ht4受体激动剂的喹啉酮-甲酰胺化合物 Download PDF

Info

Publication number
CN100569771C
CN100569771C CNB200580013391XA CN200580013391A CN100569771C CN 100569771 C CN100569771 C CN 100569771C CN B200580013391X A CNB200580013391X A CN B200580013391XA CN 200580013391 A CN200580013391 A CN 200580013391A CN 100569771 C CN100569771 C CN 100569771C
Authority
CN
China
Prior art keywords
propyl
sec
oxo
oct
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB200580013391XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1946719A (zh
Inventor
D·马克斯
P·R·法瑟里
D·S·特纳
D·D·龙
崔锡基
A·A·戈德布拉姆
D·吉诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Sigma
Original Assignee
Shiwan Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiwan Pharmaceutical filed Critical Shiwan Pharmaceutical
Publication of CN1946719A publication Critical patent/CN1946719A/zh
Application granted granted Critical
Publication of CN100569771C publication Critical patent/CN100569771C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNB200580013391XA 2004-04-07 2005-04-06 作为5-ht4受体激动剂的喹啉酮-甲酰胺化合物 Expired - Lifetime CN100569771C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56007604P 2004-04-07 2004-04-07
US60/560,076 2004-04-07

Publications (2)

Publication Number Publication Date
CN1946719A CN1946719A (zh) 2007-04-11
CN100569771C true CN100569771C (zh) 2009-12-16

Family

ID=34964334

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200580013391XA Expired - Lifetime CN100569771C (zh) 2004-04-07 2005-04-06 作为5-ht4受体激动剂的喹啉酮-甲酰胺化合物

Country Status (28)

Country Link
US (9) US7375114B2 (https=)
EP (1) EP1735304B1 (https=)
JP (2) JP4944012B2 (https=)
KR (1) KR101167296B1 (https=)
CN (1) CN100569771C (https=)
AR (1) AR050407A1 (https=)
AT (1) ATE420088T1 (https=)
AU (1) AU2005233560B2 (https=)
BR (1) BRPI0509761B8 (https=)
CA (1) CA2561558C (https=)
CY (1) CY1108908T1 (https=)
DE (1) DE602005012249D1 (https=)
DK (1) DK1735304T3 (https=)
ES (1) ES2320907T3 (https=)
HR (1) HRP20090162T1 (https=)
IL (1) IL178086A (https=)
MA (1) MA28559B1 (https=)
MX (1) MXPA06011398A (https=)
MY (1) MY155036A (https=)
NO (1) NO337126B1 (https=)
NZ (1) NZ549941A (https=)
PL (1) PL1735304T3 (https=)
PT (1) PT1735304E (https=)
RU (1) RU2394033C2 (https=)
SI (1) SI1735304T1 (https=)
TW (1) TWI351282B (https=)
WO (1) WO2005100350A1 (https=)
ZA (1) ZA200608363B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60117164T2 (de) * 2000-11-07 2006-08-03 Immuno Vaccine Technologies Inc., Halifax Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
EP1807423B1 (en) * 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
ATE469897T1 (de) * 2004-12-22 2010-06-15 Theravance Inc Indazolcarbonsäureamidverbindungen
NZ560828A (en) * 2005-03-02 2011-01-28 Theravance Inc Quinolinone compounds as 5-HT4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
US7317022B2 (en) * 2005-06-07 2008-01-08 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
CA2637214C (en) * 2006-02-16 2014-04-22 Theravance, Inc. Process for preparing 8-azabicylo[3.2.1]octan-3-one intermediates to 5-ht4 receptor agonist compounds
AU2008254999A1 (en) * 2007-05-17 2008-11-27 Theravance, Inc. Prokinetic agent for bowel preparation
TWI415850B (zh) 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CA2758321A1 (en) * 2009-04-13 2010-10-21 Theravance, Inc. 5-ht4 receptor agonist compounds for treatment of cognitive disorders
JP5540099B2 (ja) * 2009-09-14 2014-07-02 スベン ライフ サイエンシズ リミティド ５−ｈｔ４受容体リガンドとしての１，２−ジヒドロ−２−オキソキノリン化合物
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
BR112020000482A2 (pt) * 2017-07-31 2020-07-21 Theravance Biopharma R&D Ip, Llc métodos de tratamento de sintomas de gastroparesia usando velusetrag
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
US12275746B2 (en) 2022-01-11 2025-04-15 Suven Life Sciences Limited Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists
EP4590303A1 (en) 2022-09-20 2025-07-30 Alfasigma S.p.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057688A2 (en) * 2002-01-07 2003-07-17 Pfizer Japan Inc. Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321378A (en) 1979-01-16 1982-03-23 Delalande S.A. 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8527052D0 (en) 1985-11-02 1985-12-04 Beecham Group Plc Compounds
HU895334D0 (en) 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
US4948803A (en) 1986-11-21 1990-08-14 Glaxo Group Limited Medicaments for treatment on prevention of withdrawal syndrome
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
IT1231413B (it) 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
US5223511A (en) 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
IT1226389B (it) 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
US5017573A (en) 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
EP0410509A1 (en) 1989-07-25 1991-01-30 Duphar International Research B.V New substituted 1H-indazole-3-carboxamides
JPH045289A (ja) 1990-04-24 1992-01-09 Hokuriku Seiyaku Co Ltd アミド化合物
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
HU211081B (en) 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
DE69113284T2 (de) 1990-12-28 1996-02-22 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Chinolinderivat.
WO1993003725A1 (en) 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
EP0603220A1 (en) 1991-09-12 1994-06-29 Smithkline Beecham Plc Azabicyclic compounds as 5-ht 4? receptor antagonists
RU2047614C1 (ru) * 1992-06-15 1995-11-10 Джон Вайс энд Бразер Лимитед Гетероциклические соединения, или их фармацевтически приемлемые аддитивные соли кислоты, или n-оксид гетероциклического соединения, или его аддитивная соль кислоты
MX9305947A (es) 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
EP0670319A4 (en) 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS.
TW251287B (https=) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9310582D0 (en) 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
AU679336B2 (en) 1994-02-28 1997-06-26 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
US5864039A (en) 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
JP3796766B2 (ja) * 1994-05-18 2006-07-12 大正製薬株式会社 アルキル置換キノリンカルボン酸誘導体
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
US5684003A (en) 1994-10-20 1997-11-04 Nisshin Flour Milling Co., Ltd. 5-HT4 receptor agonists
JP3829880B2 (ja) 1994-12-27 2006-10-04 大正製薬株式会社 化学中間体
US5612339A (en) * 1995-01-17 1997-03-18 Trustees Of The University Of Pennsylvania 2-Hydroxy-3-aminopropylsulfonamides
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
US5654320A (en) 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
DE69627323T2 (de) 1995-05-31 2004-01-15 Nisshin Seifun Group Inc Indazolderivate mit einer cyclischen aminogruppe
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
IT1291569B1 (it) 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US5914405A (en) 1997-10-07 1999-06-22 Eli Lilly And Company Process for preparing 3-substituted indazoles
US6069152A (en) 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
FR2769915B1 (fr) 1997-10-21 2000-10-13 Synthelabo Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
IT1298271B1 (it) 1998-02-18 1999-12-20 Boehringer Ingelheim Italia Esteri ed ammidi dell'acido 2-oxo-2,3-diidro-benzimidazol-1- carbossilico
WO1999055674A1 (en) 1998-04-28 1999-11-04 Dainippon Pharmaceutical Co., Ltd. 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
KR100413150B1 (ko) 1998-09-10 2003-12-31 에프. 호프만-라 로슈 아게 5-에이치티4 수용체 길항제로서의 디하이드로벤조디옥신 카복스아미드 및 케톤 유도체
TW570920B (en) 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
FR2792318B1 (fr) 1999-04-16 2001-06-15 Synthelabo Derives d'indazole, leur preparation et leur application en therapeutique
WO2000064441A2 (en) 1999-04-28 2000-11-02 Respiratorius Ab Compound for use as a medicament for treatment of disorders involving bronchocontraction
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
IT1313625B1 (it) 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
AU2002212888A1 (en) 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6624162B2 (en) 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
JP2006502180A (ja) 2002-09-20 2006-01-19 ファイザー株式会社 ５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
BRPI0409592A (pt) 2003-04-21 2006-05-02 Pfizer compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
WO2005000837A1 (en) 2003-06-19 2005-01-06 Janssen Pharmaceutica N.V. Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
UA86204C2 (uk) 2003-09-03 2009-04-10 Пфайзер Инк. Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність
DE602004026095D1 (de) 2003-11-24 2010-04-29 Pfizer Chinoloncarbonsäureverbindungen mit 5-ht4-rezeptoragonistischer wirkung
DE602005005167T2 (de) 2004-01-29 2009-04-30 Pfizer Inc. 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
EP1807423B1 (en) * 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
ATE469897T1 (de) 2004-12-22 2010-06-15 Theravance Inc Indazolcarbonsäureamidverbindungen
NZ560828A (en) 2005-03-02 2011-01-28 Theravance Inc Quinolinone compounds as 5-HT4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
US7317022B2 (en) 2005-06-07 2008-01-08 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057688A2 (en) * 2002-01-07 2003-07-17 Pfizer Japan Inc. Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
5-HT4 Receptor Ligands: Applications and New Prospects. Michel Langlois, Rodolphe Fischmeister.JOURNAL OF MEDICINAL CHEMISTRY,Vol.46 No.3. 2003 *
Synthesis and EvaluationofNovel2-Oxo-1,2-dihydro-3-quinolinecarboxamideDerivativesasPotent andSelectiveSerotonin5-HT4ReceptorAgonists. Masaji SUZUKI,Yutaka OHUCHI.ET-AL.CHEMICAL AND PHARMACEUTICAL BULLETIN,Vol.49 No.1. 2001 *

Also Published As

Publication number Publication date
ZA200608363B (en) 2008-05-25
AR050407A1 (es) 2006-10-25
DE602005012249D1 (de) 2009-02-26
TW200536540A (en) 2005-11-16
US8962653B2 (en) 2015-02-24
HRP20090162T1 (en) 2009-05-31
MA28559B1 (fr) 2007-04-03
US20140163063A1 (en) 2014-06-12
US7592355B2 (en) 2009-09-22
HK1099019A1 (en) 2007-08-03
AU2005233560A1 (en) 2005-10-27
MY155036A (en) 2015-08-28
RU2394033C2 (ru) 2010-07-10
WO2005100350A8 (en) 2006-12-07
NO20065112L (no) 2006-12-08
JP4944012B2 (ja) 2012-05-30
DK1735304T3 (da) 2009-04-20
CA2561558C (en) 2013-06-18
US20050228014A1 (en) 2005-10-13
BRPI0509761A (pt) 2007-10-16
US20120264779A1 (en) 2012-10-18
BRPI0509761B1 (pt) 2018-07-31
EP1735304A1 (en) 2006-12-27
US7763637B2 (en) 2010-07-27
JP2007532546A (ja) 2007-11-15
JP2008174569A (ja) 2008-07-31
AU2005233560B2 (en) 2012-04-05
PT1735304E (pt) 2009-03-27
PL1735304T3 (pl) 2009-06-30
US20160376264A1 (en) 2016-12-29
CN1946719A (zh) 2007-04-11
EP1735304B1 (en) 2009-01-07
US20070270457A1 (en) 2007-11-22
NZ549941A (en) 2010-09-30
US20100311979A1 (en) 2010-12-09
BRPI0509761B8 (pt) 2021-05-25
IL178086A0 (en) 2006-12-31
CY1108908T1 (el) 2014-07-02
TWI351282B (en) 2011-11-01
US20080176895A1 (en) 2008-07-24
US9873692B2 (en) 2018-01-23
SI1735304T1 (sl) 2009-06-30
ES2320907T3 (es) 2009-05-29
US20150291580A1 (en) 2015-10-15
WO2005100350A1 (en) 2005-10-27
US20170334901A1 (en) 2017-11-23
US8575192B2 (en) 2013-11-05
US9630960B2 (en) 2017-04-25
KR101167296B1 (ko) 2012-07-23
RU2006139053A (ru) 2008-05-20
US8163920B2 (en) 2012-04-24
US7375114B2 (en) 2008-05-20
US9353106B2 (en) 2016-05-31
MXPA06011398A (es) 2006-12-20
CA2561558A1 (en) 2005-10-27
ATE420088T1 (de) 2009-01-15
NO337126B1 (no) 2016-01-25
IL178086A (en) 2011-09-27
KR20070015423A (ko) 2007-02-02

Similar Documents

Publication Publication Date Title
CN100569771C (zh) 作为5-ht4受体激动剂的喹啉酮-甲酰胺化合物
RU2404179C2 (ru) Индазол-карбоксамидные соединения
JP2012153725A (ja) キノリン−カルボキサミド化合物の結晶形態物
JP5042043B2 (ja) ５−ｈｔ４レセプターアゴニストであるキノリン化合物
US7728006B2 (en) Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
JP2008530225A (ja) インダゾール−カルボキサミド化合物の結晶型
US8309575B2 (en) Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
CN101312967B (zh) 作为5-ht4受体激动剂的氨基甲酸酯化合物
HK1099019B (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SCHWAN BIOPHARMA RESEARCH + DEVELOPMENT IP CO., LT

Free format text: FORMER OWNER: SCHWAN PHARMACY

Effective date: 20140901

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140901

Address after: California, USA

Patentee after: THERAVANCE BIOPHARMA R&D IP, LLC

Address before: California, USA

Patentee before: Shi Wanzhiyao

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250304

Address after: Bologna, Italy

Patentee after: Alpha Sigma

Country or region after: Italy

Address before: California, USA

Patentee before: THERAVANCE BIOPHARMA R&D IP, LLC

Country or region before: U.S.A.

CX01 Expiry of patent term

Granted publication date: 20091216

CX01 Expiry of patent term